Antibody Drug Conjugate Bioanalysis using the BioBA Solution

Significance of the Topic

Monoclonal antibodies and antibody-drug conjugates (ADCs) play an increasingly vital role in targeted cancer therapy due to their specificity and potency. Reliable bioanalytical quantification of ADCs such as ado-trastuzumab emtansine is critical to support drug development, dose optimization, and regulatory approval, ensuring safety and efficacy in patient treatments.

Objectives and Study Overview

This study aimed to demonstrate a robust hybrid ligand binding assay–LC/MS method for accurate quantification of the total antibody component of ado-trastuzumab emtansine in rat plasma. The BioBA High-Capacity Enrichment Sample Preparation Kit was assessed in combination with the SCIEX QTRAP® 6500+ system to simplify sample preparation, extend dynamic range, and improve selectivity while maintaining high assay performance over a wide concentration range (10–100 000 ng/mL).

Methodology and Used Instrumentation

The workflow employed immunoaffinity capture of total antibody using anti-human Fc magnetic beads, followed by on-bead reduction, alkylation, and trypsin/LysC digestion with an acid-labile mass spec surfactant. Key instrumentation components included:

• BioBA High-Capacity Enrichment Sample Preparation Kit
• Exion LC system with Phenomenex Kinetex C18 column
• SCIEX QTRAP 6500+ mass spectrometer with IonDrive Turbo V source
• MultiQuant™ software for data processing
• Biomek Fx automated liquid handling workstation (optional automation)

Chromatographic separation was achieved in a 7-minute gradient, and signature peptides IYPTNGYTR (CDR) and DTLMISR (Fc) were monitored by MRM for quantification.

Main Results and Discussion

• The assay demonstrated linearity across four orders of magnitude (10 to 100 000 ng/mL) with average accuracy between 96–105% and precision (%CV) below 9% for both signature peptides.
• Digest optimization revealed that the BioBA surfactant improved peptide yields compared to other mass spec-compatible surfactants, particularly for CDR peptides prone to deamidation.
• Lower digestion pH (~7.6) minimized asparagine deamidation of IYPTNGYTR, enhancing assay reliability.
• The internal standard (heavy-labeled DTLMISR peptide) showed consistent response (%CV ~ 13.8%), supporting robust quantitation.

Benefits and Practical Applications

The simplified kit-based immunoaffinity LC/MS workflow enables:

• Enhanced selectivity and extended dynamic range versus traditional ligand binding assays.
• Multiplexing capability to quantify additional analytes or catabolites.
• Rapid method development with minimal assay optimization.
• High throughput and reproducibility suitable for pharmacokinetic and toxicokinetic studies in preclinical and clinical settings.

Future Trends and Possibilities

Advancements may include integration of more automation for sample preparation, expansion to quantify unconjugated payload and catabolites in a single assay, and application to next-generation ADC formats with diverse linker chemistries. Coupling with high-resolution mass spectrometry could further improve characterization of heterogeneous ADC species.

Conclusion

The BioBA solution combined with the SCIEX QTRAP 6500+ system delivers a robust, accurate, and reproducible method for quantifying total antibody in ADC bioanalysis. This hybrid LBA-LC/MS approach addresses key challenges of ADC heterogeneity and supports reliable drug development workflows.